Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Researchers reporting in Aging Cell identified MTR4, an RNA helicase, as a regulator of senescence in the endothelial cells lining blood vessels. MTR4 protein levels fall with age through accelerated ubiquitin-proteasome degradation driven by SYVN1, and restoring MTR4 partially reversed senescent features and reduced inflammatory secretions in human endothelial cells. Because senescent vessel-lining cells release these compounds directly into circulation, the pathway is relevant to vascular aging and age-related cardiovascular disease.
In 223,051 men from the UK Biobank, mosaic loss of chromosome Y in blood cells independently predicted incident age-related macular degeneration, with risk escalating beyond a defined threshold of clonal burden. Plasma proteomic shifts appeared up to 15 years before diagnosis, and single-cell data localized the highest Y-loss frequencies to CD16+ monocytes and choroidal macrophages displaying a pro-inflammatory phenotype. A machine learning model built on these protein signatures predicted five-year incident risk with an AUC of 0.734.
A post-hoc analysis of Longeveron's 49-person Phase 2a CLEAR MIND trial used free water MRI to assess neuroinflammation in Alzheimer's patients treated with laromestrocel, an allogeneic mesenchymal stem cell product. Reduced inflammatory signal in the left hippocampus and temporal-parietal cortex tracked with less atrophy, better cognitive scores, and lower plasma neurogranin. The findings are exploratory, unreviewed, and hypothesis-generating rather than confirmatory.
Prenuvo has opened an imaging biobank of more than 200,000 whole-body MRI scans to over 50 research institutions, accompanied by four initial studies. The largest reported that roughly 7% of 78,000 self-referred individuals had a clinically significant brain abnormality, including aneurysms, infarcts and meningiomas. The data come from a self-selected population, and whether detection of such findings translates into longer healthy life remains unresolved.
Kailera Therapeutics has completed enrollment of roughly 4,900 participants across three Phase 3 trials of ribupatide, a once-weekly injection activating both GLP-1 and GIP receptors, with topline data expected mid-2028. One trial includes an open-label semaglutide 2.4 mg comparator arm in adults with a BMI of 35 or higher, making it a direct test against the current standard rather than placebo alone. No efficacy or safety data have been released.
Monte Rosa's MRT-8102, an oral molecular glue degrader that removes NEK7 to block NLRP3 inflammasome assembly, reduced NEK7 by 80–90% and lowered hsCRP by a median of 85%, IL-6 by 54%, fibrinogen by 28% and lipoprotein(a) by 24% in 108 adults with obesity and elevated cardiovascular risk over four weeks. Downstream plaque-associated damage signals including calprotectin, S100A12 and SAA fell by roughly half, with no increase in infections and adverse event rates comparable to placebo. The data are company-reported, biomarker-based and not yet linked to clinical outcomes.
Tenvie Therapeutics has dosed the first participant in a Phase 1 trial of TNV313, an orally administered small molecule designed to inhibit NLRP3 and cross the blood-brain barrier. The ascending-dose study in healthy volunteers will assess safety, pharmacokinetics, central nervous system distribution and exploratory pharmacodynamic biomarkers, with preliminary data expected in the first half of 2027. NLRP3-driven inflammatory signaling is implicated in neurodegenerative, cardiometabolic and ophthalmic disease, making brain-accessible inhibition a target of interest for age-related decline.
Digbi Health has extended its precision telehealth platform to all 50 states, combining genetic, gut microbiome, blood biomarker and continuous glucose data into individualized metabolic care plans that may include GLP-1 medications or hormone replacement. Peer-reviewed analysis across seven self-insured employers reported a $3,012 annual reduction in medical spend per member. The model positions multi-signal personalization — rather than single-drug prescribing — as the organizing principle of metabolic care at employer scale.
Researchers identified MTR4, an RNA helicase and nuclear exosome cofactor, as a determinant of endothelial cell youthfulness that declines sharply in senescent human endothelial cells and aged mouse aortas. Loss occurs through SYVN1-mediated ubiquitination and proteasomal degradation, destabilizing the BUB3–BUBR1 axis and triggering senescence; restoring MTR4 reversed vascular dysfunction and multi-organ aging phenotypes in mice and markedly extended lifespan in C. elegans. The vascular endothelium emerges as a tractable upstream control point for systemic aging.
Reservoir, a venture from the team behind Cellino, now offers adults cryopreservation of their own peripheral blood mononuclear cells — roughly five vials of five million cells each, collected via a standard 60-milliliter blood draw and stored below −150°C. The underlying premise is that immune cells accumulate age-related changes, including loss of naive T cells and expansion of mutated clones, so earlier samples may be more useful starting material. Whether banked cells of this quantity can serve future autologous therapies remains undetermined, as current CAR-T manufacturing typically relies on far larger apheresis collections.
A hormone-free clitoral air-pulse device has launched in UK retail pharmacy with preliminary data linking sexual stimulation to menopausal symptom relief and increased vagal tone. In a 66-woman, four-week user study, 92.9% reported improvement in at least one of more than 34 possible symptoms, a threshold met without a control group. Separate observational work in 130 menopausal women associated regular sexual activity with higher heart rate variability, consistent with greater parasympathetic regulation.
In a mouse model expressing progerin exclusively in cardiomyocytes, loss of the m6A methyltransferases METTL3 and METTL14 was sufficient to produce myocardial fibrosis, hypertrophy, and progressive functional decline. Reduced m6A writer activity suppressed the calcium-handling transcript Casq2 while raising senescence and type I interferon transcripts, and cardiomyocyte-targeted restoration of METTL14 partially reversed the pathological remodeling.